Related Experiment Video

Updated: Jul 15, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1

Jonathan M Bock1, Sarita G Menon, Prabhat C Goswami

  • 1Department of Otolaryngology--Head and Neck Surgery, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA.

Molecular Carcinogenesis
|April 7, 2007
PubMed

Insights

This study compared 10 non-steroidal anti-inflammatory drugs (NSAIDs) for head and neck cancer treatment. Celecoxib and sulindac sulfide showed the most potent antineoplastic activity by inhibiting cell cycle progression and inducing apoptosis.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used clinically.
  • Some NSAIDs exhibit antineoplastic properties, but their relative potencies and mechanisms vary.
  • Squamous cell carcinoma of the head and neck (SCCHN) is a significant health concern.

Purpose of the Study:

  • To compare the antineoplastic activity of 10 different NSAIDs against SCCHN cells.
  • To investigate the molecular mechanisms underlying the observed antineoplastic effects.
  • To identify potential therapeutic applications of NSAIDs in SCCHN treatment.

Main Methods:

  • MTT assay to determine IC(50) values for 10 NSAIDs in UM-SCC-1 cells.
  • Caspase-3 activation assay to measure apoptosis induction.
  • Cell cycle analysis (G1 phase distribution) and Western blotting for cell cycle regulators (p21, cyclin D1, Rb).
  • Luciferase reporter assay to assess E2F transactivating activity.

Main Results:

  • Celecoxib (COX-2 inhibitor) demonstrated the highest potency (IC(50) = 39.9 microM), followed by sulindac sulfide.
  • Celecoxib and sulindac sulfide significantly induced caspase-3 activation, indicating apoptosis.
  • Both agents caused a 3-fold increase in G1 phase arrest, associated with p21 induction, cyclin D1 inhibition, and Rb hypophosphorylation.
  • Downstream inhibition of E2F transactivating activity was observed with celecoxib and sulindac sulfide.

Conclusions:

  • NSAIDs exhibit a wide range of antineoplastic activities against SCCHN cells.
  • Celecoxib and sulindac sulfide possess significant anti-SCCHN potential through cell cycle inhibition and apoptosis induction.
  • The findings elucidate specific molecular mechanisms involving cell cycle regulators and E2F activity.

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...